Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CLVS

Clovis Oncology (CLVS) Stock Price, News & Analysis

Clovis Oncology logo

About Clovis Oncology Stock (NASDAQ:CLVS)

Key Stats

Today's Range
N/A
50-Day Range
$0.08
$1.09
52-Week Range
N/A
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Clovis Oncology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

CLVS MarketRank™: 

Clovis Oncology scored higher than 9% of companies evaluated by MarketBeat, and ranked 954th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Clovis Oncology.

  • Earnings Growth

    Earnings for Clovis Oncology are expected to grow in the coming year, from ($1.68) to ($0.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clovis Oncology is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clovis Oncology is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for CLVS.
  • Dividend Yield

    Clovis Oncology does not currently pay a dividend.

  • Dividend Growth

    Clovis Oncology does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CLVS.
  • Search Interest

    1 people have searched for CLVS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Clovis Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.40% of the stock of Clovis Oncology is held by insiders.

  • Percentage Held by Institutions

    Only 24.53% of the stock of Clovis Oncology is held by institutions.

  • Read more about Clovis Oncology's insider trading history.
Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

Clovis Chamber names new Retail Rockstar
Amazon coin set to soar 25X – starting December 16th?
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024
Cancer Horoscope
See More Headlines

CLVS Stock Analysis - Frequently Asked Questions

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to analysts' expectations of $38.73 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clovis Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), NIO (NIO) and Micron Technology (MU).

Company Calendar

Last Earnings
11/03/2021
Today
12/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLVS
CUSIP
18946410
Employees
N/A
Year Founded
2009

Profitability

Net Income
$-264,520,000.00
Net Margins
-189.37%
Pretax Margin
-189.68%

Debt

Sales & Book Value

Annual Sales
$148.76 million
Book Value
($2.15) per share

Miscellaneous

Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:CLVS) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners